GLP-1 Treatment Guide: Starting, Titrating, Maintaining (2026)

GLP-1 treatment is conceptually simple — you take a weekly injection or daily pill, your appetite drops, you lose weight, your metabolic markers improve. The reality is more involved: there's an evaluation phase, a titration phase that runs 4-5 months, a maintenance phase that ideally runs indefinitely, and the question of what happens if you stop.

This is the full treatment journey, from the first conversation to the long-term maintenance plan.

Phase 1: Eligibility evaluation

The first step is determining whether GLP-1 treatment is appropriate for you.

FDA-label eligibility criteria

For the weight-management GLP-1s (Wegovy, Zepbound, Saxenda, Wegovy oral, Foundayo):

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 with at least one weight-related condition (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, obstructive sleep apnea, etc.)

For T2D-indicated drugs (Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza, Byetta, Adlyxin):

• Diagnosis of type 2 diabetes

Contraindications

GLP-1s are not appropriate for:

• Personal or family history of medullary thyroid carcinoma or MEN-2
• Personal history of pancreatitis
• Severe gastroparesis
• Pregnancy or near-term pregnancy plans
• Active or recent eating disorder
• Type 1 diabetes

Baseline workup

A reasonable initial evaluation includes:

• Comprehensive medical history (especially the contraindications above)
• Weight, height, BMI, waist circumference, blood pressure
• HbA1c (diabetes screening / baseline)
• Comprehensive metabolic panel
• Lipid panel
• Thyroid function (TSH at minimum)
• Pregnancy test for patients of childbearing capacity
• Vitamin B12 and vitamin D (often deficient in weight-loss patients)

Phase 2: Drug selection

Decision factors, in order of typical impact:

1. Insurance coverage — what's covered, at what tier?
2. Indication — T2D vs weight management vs both?
3. Dosing preference — weekly injection / daily injection / daily oral?
4. Tolerability factors — comorbidities affecting drug choice
5. Cost beyond insurance — savings programs, telehealth bundles, etc.

For the head-to-head comparison, see best GLP-1 for weight loss.

Phase 3: Titration

Every approved GLP-1 follows a slow titration schedule designed to manage gastrointestinal side effects.

Typical pattern (Wegovy as example):

Tirzepatide (Zepbound/Mounjaro) follows a similar 4-weekly escalation pattern. Daily drugs (Saxenda, Foundayo) titrate weekly rather than every 4 weeks.

What to expect during titration:

• Most side effects (nausea, GI symptoms) hit hardest in the days after a dose increase, then settle within 1-2 weeks
• Weight loss is gradual through this phase — averages 1% body weight per month
• Significant weight loss usually doesn't emerge until weeks 8-12
• Most patients reach target dose by week 16-17

When to slow titration:

If side effects haven't settled within a week or two of a dose increase, the prescriber may hold the dose for an extra cycle before stepping up.

For the full dose schedules, see GLP-1 dosage for weight loss.

Phase 4: Maintenance

Once at target dose, the maintenance phase runs indefinitely for most patients.

What's involved:

• Weekly (or daily) injection / oral dose
• Monthly check-ins with the prescriber (more often early; less frequent as you stabilize)
• Regular labs: HbA1c, lipids, comprehensive metabolic panel, vitamin levels every 3-6 months
• Dose adjustments as response and tolerability change

Realistic timeline of effects:

• Months 1-6: Steady weight loss, ~1-2% body weight per month
• Months 6-12: Continued loss, trajectory slowing
• Months 12-18: Approach of plateau; trial-average weight loss reached
• Months 18+: Maintenance at the new weight; weight remains stable as long as the medication continues

Phase 5: The plateau

Weight loss plateaus by 12-18 months for most patients. This isn't failure — it's the body reaching a new homeostasis at a lower weight.

What to expect at plateau:

• Weight loss largely stops
• Appetite remains suppressed but is no longer driving deficit
• Body composition stabilizes
• Metabolic markers stabilize at improved levels

Decisions at plateau:

• Continue at maintenance dose — most common; lifelong treatment
• Reduce to lower maintenance dose — sometimes appropriate; preserves loss with lower cost and side effects
• Switch to oral maintenance — emerging option per Lilly's Foundayo Phase 3 data showing 80-95% maintenance after switching from injectable
• Discontinuation conversation — for selected patients with strong lifestyle infrastructure (resistance training, protein intake, sleep, etc.)

Phase 6: Discontinuation (when, why, what to expect)

GLP-1 discontinuation is not the standard endpoint of treatment, but it happens. Common reasons:

• Side effects persistently intolerable
• Side effects of long-term use (rare)
• Pregnancy plans
• Cost when insurance changes
• Patient choice — wanting to test maintenance off medication
• Required medical hold — surgery, illness, gastroparesis flare

What happens after discontinuation:

• Drug clearance: Semaglutide and tirzepatide take weeks to clear; liraglutide clears in 2-3 days; small-molecule oral drugs clear in days
• Appetite returns: Within 2-4 weeks for most patients
• Weight regain: Studies show patients regain 50-70% of lost weight within 12 months if they don't continue the medication or maintain with significant lifestyle change

The honest framing: GLP-1 treatment for chronic conditions (obesity, T2D) is conceptually similar to treating hypertension or high cholesterol. The condition doesn't "cure"; the treatment is ongoing.

What "good" GLP-1 treatment looks like

A few markers of well-managed treatment:

• Slow, supervised titration — not skipping steps
• Side-effect management — practical strategies, not just gritting through
• Lifestyle integration — resistance training, protein, sleep, fiber
• Regular labs and follow-up — at least every 3-6 months
• Long-term mindset — not framing this as a short course
• Honest conversations about cost, alternatives, and timeline

Red flags in GLP-1 treatment

Indicators that something needs adjustment:

• Sustained severe nausea beyond 2-3 weeks of a dose step
• Inability to keep fluids down for more than 24 hours
• Severe abdominal pain — possible pancreatitis or gallbladder
• Eating < 1,000 calories/day consistently — undereating
• Strength regression in resistance training — possible muscle loss
• Persistent low mood or anxiety
• No weight loss after 8-12 weeks at target dose — non-responder pattern, may need to switch drugs

FAQ

How long does GLP-1 treatment last? For chronic conditions (obesity, T2D), treatment is typically indefinite. Patient-specific decisions about duration are common.

Will I have to take a GLP-1 forever? Most patients do continue treatment indefinitely. Some maintain weight loss with significant lifestyle change after discontinuation; many don't.

What if a GLP-1 doesn't work for me? About 10-15% of patients are non-responders. Switching to a different GLP-1 (typically a more potent dual-receptor option) sometimes works. Pipeline drugs may help when approved.

Can I switch GLP-1s mid-treatment? Yes. Switches are common for insurance, supply, or tolerability reasons. Conversion is non-trivial and managed by the prescriber.

What's the lowest dose I should stay on long-term? The lowest effective dose that maintains your weight and tolerates well. Discuss with your prescriber.

This article is for educational purposes only and is not medical advice. GLP-1 treatment is highly individual. Discuss your treatment plan with a qualified healthcare professional.